# ClinicalTrials.gov record NCT05616013

> PeptideScanner retained ClinicalTrials.gov record NCT05616013 at 2026-08-10T18:10:03.915Z. Its registry update date was 2026-07-08, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct05616013-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-08
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05616013-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct05616013-semaglutide-v1.json
- Content SHA-256: `a904d483f6ed58f129cdc5ea6fdc78de472f3bc52cc8de032e6e7f4a7c6a8503`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT05616013 ([`ctg-observation-nct05616013-2026-07-08-d9478eaca1f6`](#source-ctg-observation-nct05616013-2026-07-08-d9478eaca1f6))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05616013 at 2026-08-10T18:10:03.915Z. Its registry update date was 2026-07-08, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05616013-2026-07-08-d9478eaca1f6`](#source-ctg-observation-nct05616013-2026-07-08-d9478eaca1f6))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05616013 at 2026-08-10T18:10:03.915Z. Its registry update date was 2026-07-08, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05616013-2026-07-08-d9478eaca1f6`](#source-ctg-observation-nct05616013-2026-07-08-d9478eaca1f6))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05616013-2026-07-08-d9478eaca1f6`](#source-ctg-observation-nct05616013-2026-07-08-d9478eaca1f6))

## Sources

<a id="source-ctg-observation-nct05616013-2026-07-08-d9478eaca1f6"></a>
- **ClinicalTrials.gov record NCT05616013 · retained source version 2026-07-08:d9478eaca1f6c61ed090c1e67a95b9b91626e423f9f5125319e069d2bea6bd1a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05616013) (`ctg-observation-nct05616013-2026-07-08-d9478eaca1f6`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05616013." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct05616013-semaglutide-v1.json SHA-256: a904d483f6ed58f129cdc5ea6fdc78de472f3bc52cc8de032e6e7f4a7c6a8503.